The S&P 500, predictably, went down. 2.06%. Because of course it did. The Nasdaq Composite, same story. 2.39%. It’s like a coordinated effort to make me feel bad about my portfolio. Moderna was up, though. 4.56%. And Novavax? Up a measly 0.49%. Like they’re trying to send a message. “See? Some biotech stocks go up. You’re just unlucky.” It’s infuriating.
The question, of course, is not merely one of past performance, but of future probability. To fixate on short-term gains is to mistake a ripple for the tide. IonQ, having demonstrated a rather impressive fidelity – a 99.99% accuracy in its two-qubit gates, a figure that, while technically noteworthy, feels suspiciously close to a magician revealing a cleverly concealed card – has established itself as a frontrunner in a race that, let us be frank, may not reach the finish line for a decade, or even two. This achievement, this near-perfection, is less a breakthrough than a tantalizing glimpse of the plateau that still looms in the distance.
Now, the yen’s sudden spurt wasn’t just a fluke of nature-oh no, it was cooked up by a couple of clever schemes from them bigwigs at the central banks. First off, the New York Federal Reserve-those crafty Yankees-decided to play post office with the banks, checking rates like they were shopping for a Sunday hat. This little maneuver is the financial equivalent of a sheriff tipping his hat before he shoots-a sign that intervention might be a-comin’.
According to a recent filing with the Securities and Exchange Commission (SEC), a body dedicated to ensuring that everyone understands absolutely nothing, Pursue Wealth Partners LLC divested its entire stake in Advance Auto Parts. The filing, a document composed entirely of fine print and legalese, confirmed that the fund now holds zero shares. Zero. A truly astonishing number. (It’s one less than one, if you’re keeping track.)
But hold on to your hats, because here comes the punchline. After all this… success… the market is starting to look a little… suspicious. Like a magician who keeps pulling the same rabbit out of the hat. And history, bless its dusty heart, is trying to warn us. So, let’s talk about 2026 and beyond, shall we? Don’t say I didn’t warn you when your yacht suddenly shrinks.
Precedence Research suggests the global AI chip market could expand at a CAGR of 27.9% from 2026 to 2035. A significant number, certainly. Though, when you consider the sheer volume of data being generated – everything from cat pictures to complex financial models – it’s almost…inevitable. (And yet, we still find ourselves surprised. Humans. Go figure.) To capitalize on this decidedly secular trend – and, let’s be honest, to potentially earn a return on investment – one might consider a look at three of the most closely followed players in the AI chip arena: Nvidia (NVDA 0.65%), AMD (AMD 3.26%), and Broadcom (AVGO +1.41%).
The sudden departure of a chief financial officer is rarely a cause for celebration. In this instance, however, the swiftness of the transition—Alex Kayyal, scarcely settled into the role, now relinquishing it—introduces a note of particular unease. One is reminded of a traveler abruptly abandoning a journey, leaving unanswered the question of what prompted such haste.
Three point two million bucks, give or take. That’s what Sather dropped on those shares. Calculated by the market’s whim, the average closing price. But here’s the rub. The whole position, even with the new additions, lost nine point three two million. The stock’s been circling the drain, and even new money can’t entirely plug the leak.
The answer, as these things often are, resides in valuation. A price, it appears, ventured too far ahead of the underlying reality, a phantom limb extending beyond the body of the business itself.
Indeed, the company has, in recent years, experienced periods of undeniable difficulty, though a degree of improvement has lately been reported. It remains to be seen whether this is a genuine recovery, or merely a temporary respite before a further decline. The discerning investor must, therefore, proceed with caution, and endeavor to ascertain whether Macy’s shares represent a true opportunity, or a cleverly disguised disappointment.